Zinaida Good

60 posts

Zinaida Good banner
Zinaida Good

Zinaida Good

@GoodZinaida

Assistant Professor of Medicine at Stanford University

Palo Alto, CA Katılım Aralık 2014
126 Takip Edilen1.1K Takipçiler
Zinaida Good retweetledi
Roth_Lab
Roth_Lab@Roth_Lab·
Excited to present the first major work after starting our lab at Stanford and the Arc this year: CRISPR-All, a unified genetic perturbation language for programming any major type of genetic perturbation simultaneously, in any combination, at genome scale, in human cells.
English
9
103
403
153.7K
Zinaida Good
Zinaida Good@GoodZinaida·
We're excited to release tcellMIL, an attention-based multiple instance learning model for predicting patient outcomes after CAR T cell therapy for lymphoma and nominating cell design strategies in #neurips2025 AI4D3! ai4d3.github.io/2025/papers/16…
English
2
6
37
3.3K
Zinaida Good
Zinaida Good@GoodZinaida·
This would not be possible without my mentors, especially Crystal Mackall, @sylviaplevritis, @GarryPNolan, Sean Bendall, David Miklos, and Michael Gold - THANK YOU!
English
1
0
27
6.4K
Zinaida Good
Zinaida Good@GoodZinaida·
Today is my first day as an Assistant Professor of Medicine at Stanford University! My research program is focused on understanding and enhancing engineered T cell immunotherapies for cancer and immune-mediated diseases. If interested in joining please reach out!
English
84
174
1.6K
112K
Zinaida Good
Zinaida Good@GoodZinaida·
Very proud of Anne Marijn Kramer to present 2 orals and a poster at #ASH2024, especially our work on CD22-CAR! Session 702 Dec 9 at 2:45 PM San Diego Convention Center, Room 6CF Title: CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with IEC-HS
English
1
0
10
3.3K
Zinaida Good
Zinaida Good@GoodZinaida·
So proud of Kelvin Mo to give his first talk at #ASH2024! Session 702 Dec 7 at 4:00 PM Manchester Grand Hyatt San Diego, Grand Hall C Title: CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL
English
0
0
4
2.1K
Zinaida Good
Zinaida Good@GoodZinaida·
What an honor to give my first invited talk at #ASH2024. I am so grateful to my mentors Crystal Mackall, Sylvia Plevritis, and David Miklos for enabling me to get here! Dec 8 at 4:30 PM, San Diego Conv. Center, Room 33 Cellular Heterogeneity and Relationship to Clinical Outcomes
English
0
0
12
1.4K
Zinaida Good retweetledi
Cee Cee Schnugg
Cee Cee Schnugg@ceeceeboom·
Boom Capital is hiring a Chief of Staff. 🚀 This is one of our most important hires. You'll liaise with our in-house scientific society and impact every aspect of a VC firm, serving unprecedented ideas, scientists and engineers. Join boomcap.co and apply here: tinyurl.com/2xm65tja
English
7
27
79
40.8K
Caleb Lareau
Caleb Lareau@CalebLareau·
Out today in @Nature, we describe HHV-6 reactivation in T cells, including therapeutic CAR T cells. I’m so grateful to have worked with an all-star team during my time in the @Satpathology lab that led to these findings. nature.com/articles/s4158… 1/n
English
19
116
445
89.7K
Zinaida Good
Zinaida Good@GoodZinaida·
Honored to be interviewed by @10xGenomics to discuss our work with @SRamakrishna_MD , @MackallLab, and @michelle_monje on GD2-CAR T cell therapy for pediatric brain cancer.
10x Genomics@10xGenomics

#CART therapy is a good treatment for blood cancers, and @SRamakrishna_MD and @GoodZinaida think it has potential for kids with fatal brain cancer, too. Hear more about their #singlecell study, in collaboration with @parkerici, in our latest blog post ⬇️ 10xgen.com/3ZMqWoF

English
0
0
17
2.4K
Zinaida Good
Zinaida Good@GoodZinaida·
Thanks @TeikoBio for highlighting our work with @jayspiegel25, @BitaSahaf, @MackallLab, David Miklos, and team on defining the role of CAR Treg cells in progression following #CART therapy for lymphoma.
Teiko@TeikoLabsHQ

Axi-cel is effective in only 40% of large B cell lymphoma (LBCL) patients and 69% experience neurotoxicity. Using mass cytometry, @GoodZinaida et al profiled post-infusion CAR T cells in LBCL patients to identify markers of response and neurotoxicity. teiko.bio/good-2022

English
0
0
7
1.4K
Kole Roybal
Kole Roybal@KoleRoybal·
Congrats to @dbgoodman @CamilliaAzimi and team for an incredible story on high-throughput design and characterization of CARs - 'CarPooling'. Check out how a signaling domain primarily found in B cells can improve a clinical grade FDA-approved CAR... tinyurl.com/yck6excz
Courtney Malo@courtney_malo

Three research articles wrap up the special issue sharing new data on "CAR Pooling" (@KoleRoybal), modulating transription factors to improve CAR T cells, and a CD22-targeted CD28 bispecific antibody (@Regeneron).

English
1
11
43
0
SpitzerLab
SpitzerLab@SpitzerLab·
Excited to share our new paper in @NatureMedicine in which we demonstrate that tumor burden dynamically reshapes the composition and function of the immune macroenvironment. Here are some of the main highlights! go.nature.com/3c4CjzP 1/7
English
5
86
232
0
Max Mamonkin
Max Mamonkin@MaxMamonkin·
Back in 2018, we were working to move our CD7 CARTs (CRISPR-edited for CD7 to avoid fratricide) to a Phase I but the regulatory hurdles for gene-edited CARTs were too high for a small academic group. That got us thinking, do we need gene editing at all? 1/ cell.com/molecular-ther…
English
12
23
108
0

Keşfet

@sylviaplevritis @GarryPNolan @CalebLareau @Nature @Satpathology @parkerici @CGT_Live @BitaSahaf